Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patients with Atr
January 22, 2025 17:00 ET | Source: Anthos Therapeutics Secondary endpoints also…
Cooler Master Unveils the Ncore 100 Air: Compact Design Made for Easy PC Building and Upgrades
Space-Saving Design Meets High Performance in a Sleek, Minimalistic Form FactorTAIPEI, Taiwan--(BUSINESS…
Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025 16:59 ET | Source: Shattuck Labs, Inc. AUSTIN, TX…
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban
November 16, 2024 16:38 ET | Source: Anthos Therapeutics Data presented at…
Innodisk Introduces E1.S Edge Server SSD for the Future of Edge Computing and AI
TAIPEI, Nov. 13, 2024 /PRNewswire/ -- Innodisk, a leading global AI solution…
